Agenus Inc. (NASDAQ:AGEN) Receives Average Recommendation of “Hold” from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have earned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the company, Marketbeat reports. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $10.00.

AGEN has been the topic of several analyst reports. HC Wainwright reduced their target price on Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Tuesday, November 12th. B. Riley decreased their price objective on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Finally, StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th.

Agenus Price Performance

AGEN opened at $3.55 on Thursday. Agenus has a fifty-two week low of $2.50 and a fifty-two week high of $19.69. The company’s 50 day moving average price is $4.36 and its two-hundred day moving average price is $8.25. The firm has a market capitalization of $83.28 million, a price-to-earnings ratio of -0.32 and a beta of 1.39.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 DIFC Ltd acquired a new position in shares of Agenus during the second quarter valued at about $51,000. EP Wealth Advisors LLC bought a new stake in Agenus in the 3rd quarter valued at about $55,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Agenus during the 2nd quarter worth approximately $106,000. BNP Paribas Financial Markets boosted its holdings in Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 84,477 shares in the last quarter. Finally, HighTower Advisors LLC grew its stake in Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 7,530 shares during the period. 61.46% of the stock is owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.